Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported Q2 2017 earnings this Afternoon, coming in at ($0.77) per share, missing Wall Street’s estimates of ($0.74) per Share. Revenue for the quarter came in at $6.49 million beating analyst estimates of $5.58 million
Analyst Coverage For Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
These are 3 Hold Ratings, 6 Buy Ratings .
The current consensus rating for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is Buy (Score: 2.67) with a consensus target price of $38.83 , a potential (66.24% upside)Recent Insider Trading for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
- On 5/12/2017 Amit Munshi, Insider, bought 25,000 with an average share price of $1.19 per share and the total transaction amounting to $29,750.00.
- On 4/26/2017 Amit Munshi, Insider, bought 50,000 with an average share price of $1.41 per share and the total transaction amounting to $70,500.00.
- On 6/13/2016 Christine Anna White, Director, sold 18,728 with an average share price of $1.99 per share and the total transaction amounting to $37,268.72.
- On 3/30/2015 Randall E Woods, Director, sold 76,268 with an average share price of $4.49 per share and the total transaction amounting to $342,443.32.
- On 3/17/2015 Steven W Spector, EVP, sold 70,000 with an average share price of $5.00 per share and the total transaction amounting to $350,000.00.
- On 1/8/2015 Steven W Spector, EVP, sold 45,000 with an average share price of $6.26 per share and the total transaction amounting to $281,700.00.
Recent Trading for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Shares of Arena Pharmaceuticals, Inc. closed the previous trading session at 23.36 up +0.10 0.43% with 502,285 shares trading hands.